Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month High – What’s Next?

Maze Therapeutics, Inc. (NASDAQ:MAZE) hit a new 52-week high during trading on Monday . The company traded as high as $37.44 and last traded at $36.88, with a volume of 8741 shares. The stock had previously closed at $36.26.

Analyst Ratings Changes

A number of research firms have recently weighed in on MAZE. Guggenheim boosted their price objective on shares of Maze Therapeutics from $19.00 to $34.00 and gave the company a “buy” rating in a research report on Monday, September 15th. Raymond James Financial initiated coverage on shares of Maze Therapeutics in a research note on Thursday, November 13th. They issued an “outperform” rating and a $48.00 target price for the company. JPMorgan Chase & Co. increased their price target on Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a research note on Monday, September 29th. Wedbush raised their price objective on Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Finally, Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $38.57.

Maze Therapeutics Trading Up 1.8%

The firm has a market capitalization of $1.78 billion and a PE ratio of -1.77. The firm has a 50-day moving average of $29.10 and a two-hundred day moving average of $19.01.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.08.

Insider Buying and Selling at Maze Therapeutics

In other news, Director Richard H. Scheller sold 20,744 shares of the business’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Ameritas Investment Partners Inc. grew its stake in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after buying an additional 738 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after acquiring an additional 1,725 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Maze Therapeutics during the 3rd quarter worth $52,000. CWM LLC acquired a new stake in Maze Therapeutics in the 2nd quarter valued at $28,000. Finally, New York State Common Retirement Fund purchased a new position in Maze Therapeutics in the first quarter valued at about $25,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.